drugset / Trial / NCT07294235
A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
Phase 1
Recruiting
60 enrolled
BrightGene Bio-Medical Technology Co., Ltd.
BrightGene Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the pharmacokinetic profile of BGM1812 in the bloodstream.
Timeline
- Start
- 2025-12-05
- Primary completion
- 2026-03-02
- Completion
- 2026-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGM1812 | Unknown | — | Subcutaneous |